ALK-targeted adjuvant treatment in NSCLC: A Case Report
https://doi.org/10.21518/ms2025-239
Abstract
Non-small cell lung cancer (NSCLC) is the second most common malignancy and the leading cause of cancer-related death worldwide. Platinum-based chemotherapy has been the standard of postsurgery care for early and locally advanced disease for many years, which only accounted for 4–5% increase in 5-year survival. Recent advances in biomarkers have altered the drug treatment paradigm for patients with NSCLC, first of all for advanced stages of disease. They were predictably integrated and successfully applied in the adjuvant settings, resulting in significant improvements in cancer care outcomes. Osimertinib was the first example of effective adjuvant targeted therapy in NSCLC for the treatment of tumours with epidermal growth factor receptor (EGFR) mutations, which updated the feasibility of using this strategy for other oncogenic drivers, in particular, ALK translocation. The Food and Drug Administration (FDA) approved alectinib as adjuvant treatment for anaplastic lymphoma kinase (ALK)-positive NSCLC on April 18, 2024. This approval was based on the results of the ALINA trial, which demonstrated that alectinib significantly prolonged a disease-free survival compared with the standard platinum-based chemotherapy. The clinical case described in the article demonstrates the experience of treating a 41-year-old woman with ALK-positive stage IIIA NSCLC, who started the postoperative therapy with alectinib after surgical treatment in November 2023.
About the Authors
A. L. Kornietskaya
Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Аnna L. Kornietskaya, Cand. Sci. (Med.), Senior Researcher, Department of Chemotherapy
3, 2nd Botkinskiy Proezd, Moscow, 125834
S. F. Evdokimova
Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Sevindzh F. Evdokimova, Cand. Sci. (Med.), Oncologist, Department of Chemotherapy
3, 2nd Botkinskiy Proezd, Moscow, 125834
L. V. Bolotina
Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Center
Russian Federation
Russian Federation
Larisa V. Bolotina, Dr. Sci. (Med.), Head of Chemotherapy Department
3, 2nd Botkinskiy Proezd, Moscow, 125834
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.
3. Vansteenkiste J, Wauters E, Reymen B, Ackermann CJ, Peters S, De Ruysscher D. Current status of immune checkpoint inhibition in earlystage NSCLC. Ann Oncol. 2019;30(8):1244–1253. https://doi.org/10.1093/annonc/mdz175.
4. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009.
5. Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. Clin Cancer Res. 2016;22(18):4585–4593. https://doi.org/10.1158/1078-0432.CCR-15-3101.
6. Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321–1328. https://doi.org/10.1093/annonc/mdz167.
7. Yang JC, Lee DH, Lee JS, Fan Y, de Marinis F, Iwama E et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study. J Clin Oncol. 2023;41(17 Suppl.):LBA9000-LBA9000. https://doi.org/10.1200/JCO.23.02747.
8. Mok TSK, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR et al. LBA1568: nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Ann Oncol. 2022;33:S1561–S1562. https://doi.org/10.1016/j.annonc.2022.10.350.
9. Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J et al. PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13(9):1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013.
10. Zito Marino F, Botti G, Aquino G, Ferrero S, Gaudioso G, Palleschi A et al. Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC. Int J Mol Sci. 2020;21(14):4927. https://doi.org/10.3390/ijms21144927.
11. Remon J, Pignataro D, Novello S, Passiglia F. Current treatment and future challenges in ROS1and ALK-rearranged advanced non-small cell lung cancer. Cancer Treat Rev. 2021;95:102178. https://doi.org/10.1016/j.ctrv.2021.102178.
12. Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer. 2018;122:67–71. https://doi.org/10.1016/j.lungcan.2018.05.020.
13. Solomon B, Ahn J, Dziadziuszko R, Barlesi F, Nishio M, Lee D et al. LBA2 ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(Suppl. 2):S1295–S1296. https://doi.org/10.1016/j.annonc.2023.10.051.
14. Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024;390(14):1265–1276. https://doi.org/10.1056/NEJMoa2310532.
15. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340–2366. https://doi.org/10.1093/annonc/mdx310.
16. Gyawali B, Hwang TJ, Vokinger KN, Booth CM, Amir E, Tibau A. PatientCentered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. Am Soc Clin Oncol Educ Book. 2019;39:374–387. https://doi.org/10.1200/EDBK_242229.
17. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M et al.; ADAURA Investigators. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711–1723. https://doi.org/10.1056/NEJMoa2027071.
18. Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023;41(10):1830–1840 https://doi.org/10.1200/JCO.22.02186.
19. Solomon B, Wu Y, Dziadziuszko R, Barlesi F, Nishio M, Ahn J et al. 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Ann Oncol. 2024;35(2):S775. https://doi.org/ 10.1016/j.annonc.2024.08.1265.
Review
For citations:
Kornietskaya AL, Evdokimova SF, Bolotina LV. ALK-targeted adjuvant treatment in NSCLC: A Case Report. Meditsinskiy sovet = Medical Council. 2025;(10):149-153. (In Russ.) https://doi.org/10.21518/ms2025-239
Views:
26
Email this article 